Dr. Marileila Varella Garcia Joins Biocept as Scientific Advisor
One of Dr. Garcia's primary areas of interest includes developing and validating companion diagnostic (CDx) tests, which analyze biomarkers that are used by physicians when making patient treatment decisions about whether to prescribe drugs such as Herceptin® (trastuzumab), Xalkori® (crizotinib) and Zykadia™ (ceritinib). Many of these biomarkers are included today in Biocept's liquid biopsy test menu including ALK, HER2, ROS1, and MET.
"Dr. Garcia's expertise in validating and developing personalized
medicine assays affords us the opportunity to further expand the breadth
and depth of our clinical laboratory assays, which are designed to
qualify patients for existing and emerging cancer therapies based on a
tumor's genetic signature," said
"I am excited to collaborate with
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to our impact on diagnostic
strategies, our ability to expand the breadth and depth of our clinical
laboratory assays, our ability to enhance our services, the ability of
our platform to integrate different assays and the benefits thereof, and
our planned future offerings, such statements are forward-looking, and
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned not to
put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150803005325/en/
Investor Contact:
LHA
jcain@lhai.com
Source:
News Provided by Acquire Media